Former FDA Commissioner Donald Kennedy: Lessons From A Different Era
Donald Kennedy has passed away after contracting COVID-19 in a nursing home. Even 40 years after he ran FDA, a remarkable number of themes of his tenure still resonate.
You may also be interested in...
Four ex-commissioners outline their ideas for reforming the Food & Drug Administration. They don't think new ideas are necessary: just follow through on their old favorites.
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.
Whether CME for pain management has the intended impact on prescribing is likely focus of new ‘suite of studies’ intended to assess the opioid REMS program. The challenges for FDA include teasing out the impact of the risk management program amid all the other public health efforts on opioids.